ABSTRACT
A literature review is presented regarding studies of systemic and side effects of corticosteroids for topical treatment in the airways. Systemic effects studied are plasma and urine cortisol, with and without cosyntropin stimulation test. Generally, doses lower than 400 microg had no discernible effects. All studies found were performed on adults. Side effects are, e.g. cataract, septal perforation, and bone growth retardation. The latter side effect is studied in children with asthma, e.g. with knemometry. Generally, doses of 400 microg a day or less of 'modern' corticosteroids did not reduce the growth rate. No report is found concerning septal perforation in children.
Subject(s)
Glucocorticoids/therapeutic use , Rhinitis, Allergic, Perennial/drug therapy , Adult , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Bone Development/drug effects , Child , Glucocorticoids/adverse effects , Humans , SteroidsABSTRACT
BACKGROUND: The aim of this paper was to investigate the role of SLPI in patients with allergic rhinitis. From this point of view, we also examined leukocyte elastase, alpha1-antitrypsin, and albumin. SLPI is an inhibitor of serine proteases such as leukocyte elastase, cathepsin G, and mast-cell chymase. Since chymase is considered to participate in mast-cell degranulation and histamine release, SLPI might act as a regulator of allergic reactions. Recent interest has been focused on leukocytes and allergy. Since SLPI is a strong inhibitor of leukocyte elastase, we also focused on the function of elastase in allergic rhinitis. METHODS: We used the method of nasal lavage after unilateral nasal antigen challenge in atopic and healthy subjects. The ELISA quantified SLPI and elastase. Albumin and alpha1-antitrypsin were quantified by electroimmunoassay. Gel filtration was used to separate native SLPI from its complex with elastase. RESULTS: There was a higher level of SLPI in lavage fluid from healthy subjects than from atopic patients. SLPI was increased on the contralateral side in atopic subjects after allergen challenge. The absence of increase in SLPI on the challenged side may be attributed to the increase in elastase and its binding to SLPI, which might have an effect on the immunoreactivity and interfere with the ELISA. It may then be assumed that there is an augmentation of SLPI on the challenged side as well. No increase was seen in healthy subjects. There was a higher concentration of elastase, alpha1-antitrypsin, and albumin before antigen challenge in atopic patients outside the pollen season than in healthy subjects. As expected, an increase was also seen in the challenged side exclusively in atopic subjects. CONCLUSIONS: The lower concentration of SLPI in nasal lavage fluid among the atopic patients than the healthy subjects indicates damaged mucosa. Neural reflexes are involved in SLPI release since there was an increase even in the contralateral nostril. A higher level of elastase and albumin before allergen challenge suggests chronic inflammation in nasal mucosa outside the pollen season. Leukocyte recruitment takes place in response to IgE-mediated reactions, which are reflected in an increase in elastase in response to allergen challenge.
Subject(s)
Albumins/analysis , Leukocyte Elastase/analysis , Nasal Mucosa/metabolism , Nasal Provocation Tests , Proteins/analysis , Rhinitis, Allergic, Seasonal/immunology , Serine Proteinase Inhibitors/analysis , alpha 1-Antitrypsin/analysis , Adult , Chromatography, Gel , Enzyme-Linked Immunosorbent Assay , Humans , Immunoassay , Middle Aged , Nasal Lavage Fluid/chemistry , Nasal Provocation Tests/methods , Proteinase Inhibitory Proteins, Secretory , Secretory Leukocyte Peptidase InhibitorSubject(s)
Adrenal Cortex Hormones/adverse effects , Asthma/drug therapy , Dermatitis, Allergic Contact/etiology , Rhinitis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Anti-Inflammatory Agents/adverse effects , Budesonide/adverse effects , Drug Eruptions/etiology , Humans , Hydrocortisone/adverse effects , Hydrocortisone/analogs & derivatives , Patch TestsABSTRACT
BACKGROUND: This study aimed to investigate the influence of patient selection criteria, i.e., mite-allergic individuals exposed and not exposed to Dermatophagoides siboney and Blomia tropicalis, on the biologic activity of mite extracts. Determination of the potency of mite extracts in vivo requires selection of patients with a clinical history of mite allergy. In Scandinavia, there are some anamnestic criteria for mite allergy, whereas in the tropics, where patients are continuously exposed to high levels of mites, selection of patients with mite allergy by clinical history is difficult. METHODS: A total of 210 Cuban asthmatics with continuous symptoms, and 43 Swedes with a clinical history of mite allergy were investigated. Skin prick tests were performed with D. siboney, D. pteronyssinus, D. farinae, B. tropicalis, Acarus siro, Lepidoglyphus destructor, and Tyrophagus putrescentiae extracts. For analysis of the biologic activity of mite extracts, Cuban patients were divided into four groups: 1) all patients skin-test-positive to mites 2) patients positive to mites, but not to other inhalant allergens 3) patients reacting most to the mite species analyzed 4) patients reactive only to mites and reacting most to the mite species analyzed. The biologic potency was calculated according to the Nordic Guidelines. RESULTS: Due to cross-reactivity between mites, Swedish mite-sensitive patients, with a clear clinical history of mite allergy, but not exposed to D. siboney and B. tropicalis, were more skin reactive to these mites than were Cubans. The estimated potency increased gradually to >200% in group 4. In group 1 Cubans, the reactivity to all mites but B. tropicalis was lower than that in mite-sensitive Swedes. CONCLUSIONS: According to the influence of patient selection criteria on the estimation of the potency of mite extracts, the determination of the biologic activity of allergenic extracts in subjects without a clear-cut clinical history should be replaced by new methods when available.
Subject(s)
Allergens/immunology , Allergy and Immunology/standards , Glycoproteins/immunology , Mites/immunology , Adolescent , Adult , Aged , Animals , Antigens, Dermatophagoides , Asthma/immunology , Child , Child, Preschool , Climate , Cuba , Humans , Hypersensitivity/immunology , Middle Aged , Patient Selection , Skin Tests , SwedenSubject(s)
Anti-Inflammatory Agents/adverse effects , Budesonide/adverse effects , Dermatitis, Allergic Contact/etiology , Administration, Topical , Adult , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Budesonide/administration & dosage , Budesonide/therapeutic use , Dose-Response Relationship, Drug , Female , Glucocorticoids , Humans , Nasal Septum/drug effects , Nasal Septum/pathology , Patch Tests , Rhinitis, Vasomotor/drug therapyABSTRACT
The long-term effect of tree pollen extract immunotherapy was investigated 6 years after termination of the treatment. Subjective symptom evaluation of 36 patients 6 years after a 3-year period of immunotherapy showed that rhinitis and asthma symptoms remained at the improved level reached just after termination of the treatment. Some 86% of the rhinitis patients and 68% of the asthma patients maintained improvement. None of the rhinitis patients developed asthma in the study period. Skin prick tests reflected the outcome of the subjective symptom assessment. The skin sensitivity of the patients decreased significantly during immunotherapy, and the skin reactions 6 years after specific immunotherapy were still significantly lower than the pretreatment levels. Total IgE and birch-specific IgE levels were constant throughout the study period, and both the affinity and epitope specificity of the IgE antibodies of the patients were the same before, during, and 6 years after treatment. In conclusion, specific immunotherapy reduces symptoms in patients suffering from rhinitis and asthma, and the effect is maintained 6 years after termination of the treatment. Specific immunotherapy seems to prevent long-term development of asthma in rhinitis patients. IgE measurements do not reflect the overall status of the patients.
Subject(s)
Allergens , Asthma/prevention & control , Desensitization, Immunologic/standards , Pollen , Rhinitis, Allergic, Seasonal/prevention & control , Asthma/immunology , Desensitization, Immunologic/methods , Follow-Up Studies , Humans , Immunoglobulin E/blood , Rhinitis, Allergic, Seasonal/immunology , Skin Tests , Time Factors , Treatment Outcome , TreesABSTRACT
Two topical corticosteroids, budesonide (BUD) and beclomethasone dipropionate (BDP), both administered as suspensions in water, were investigated in healthy volunteers regarding influence on cortisol in plasma and urine (U-cortisol) after nasal application. In the first study, single doses of 200, 400, and 800 micrograms of BDP and BUD were given at 10:00 pm. In the second study, 100, 200, and 400 micrograms were given mornings and evenings for 4 days. In the single-dose study, none of the drugs or doses showed any significant influence on cortisol in plasma. However, U-cortisol decreased significantly after BUD 400 and 800 micrograms. In the multidose study, U-cortisol values were significantly reduced after all doses of BUD and the highest dose of BDP. The compounds tested showed different ability to cause measurable systemic effects after nasal application. The clinical implication is that the prescriber, when choosing a compound, should take the application site into consideration and should also be encouraged to find the lowest effective dose.
Subject(s)
Beclomethasone/administration & dosage , Beclomethasone/adverse effects , Hypothalamo-Hypophyseal System/drug effects , Pituitary-Adrenal System/drug effects , Pregnenediones/administration & dosage , Pregnenediones/adverse effects , Administration, Intranasal , Adolescent , Adult , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/adverse effects , Budesonide , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Male , Middle AgedSubject(s)
Anti-Allergic Agents/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Dose-Response Relationship, Drug , Histamine H1 Antagonists/administration & dosage , Terfenadine/administration & dosage , Catalogs, Drug as Topic , Drug Prescriptions , Humans , Sweden , Terfenadine/adverse effectsSubject(s)
Anti-Asthmatic Agents/administration & dosage , Histamine H1 Antagonists/administration & dosage , Terfenadine/administration & dosage , Anti-Asthmatic Agents/adverse effects , Dose-Response Relationship, Drug , Drug Information Services , Histamine H1 Antagonists/adverse effects , Humans , Terfenadine/adverse effectsABSTRACT
The concentration of biomarkers from vessels and inflammatory cells in nasal lavage fluid reflects the degree of hyperresponsiveness in patients with allergic rhinitis. The lavage has usually been performed of both nasal cavities together after prewashings and administration of decongestants. To improve the technique, we introduced a modification involving lavage of the nasal cavities separately without any prewashings or decongestants. We challenged 20 rhinitic subjects sensitive to timothy unilaterally with timothy extract. In nasal lavages performed before, immediately after, and 6 h after the challenge, we determined the concentrations of albumin, histamine, bradykinin, TAME (N-alpha-tosyl-L-arginine methyl ester)-esterase, and leukotriene C4 (LTC4). In eight subjects, the procedure was repeated 1 and 2 weeks later. After the challenge, albumin, bradykinin, TAME-esterase, and LTC4 in the nasal lavage fluid increased on the ipsilateral side but not on the contralateral side. Histamine did not increase after antigen challenge. After 6 h, the biomarkers were not increased. The concentrations of biomarkers did not differ between sides before the challenge and not between visits. Thus, the modified nasal lavage technique is reliable and improved compared to previous methods because it involves reproducible determinations of different biomarkers, and it is simple and easy to perform.
Subject(s)
Antigens/immunology , Biomarkers/analysis , Nasal Lavage Fluid/immunology , Nose , Therapeutic Irrigation/methods , Adolescent , Adult , Albumins/analysis , Allergens/immunology , Bradykinin/analysis , Female , Histamine/analysis , Humans , Male , Peptide Hydrolases/analysis , Poaceae/immunology , Pollen/immunology , Rhinitis, Allergic, Perennial/immunology , Seasons , Time FactorsABSTRACT
The specificity pattern of IgE from non-treated tree pollen allergic patients (n = 38) were evaluated by solid phase absorption of serum samples followed by CRIE on alder, birch and hazel CIE precipitation profiles. The majority of the serum samples seemed to contain IgE antibodies with the following characteristics: specific towards Bet v I alone and common between Aln g I, Bet v I and/or Cor a I, 'II'. The IgE specificity profiles observed for 95% of the sera tested are compatible with birch pollen allergens being the only sensitizing allergens, indicating that the patients react to allergens from other tree pollens of the Fagales order due to IgE cross-reaction with the major allergens of birch and alder and/or hazel pollens.
Subject(s)
Allergens/immunology , Epitopes/analysis , Immunoglobulin E/analysis , Plant Proteins/immunology , Antibodies/analysis , Antibodies/immunology , Antibody Specificity , Antigens, Plant , Autoradiography , Cross Reactions/immunology , Humans , Hypersensitivity/blood , Hypersensitivity/immunology , Immunoglobulin E/immunologySubject(s)
Conjunctivitis, Allergic/drug therapy , Cromolyn Sodium/therapeutic use , Histamine H1 Antagonists/therapeutic use , Piperidines/therapeutic use , Adolescent , Adult , Cohort Studies , Cromolyn Sodium/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Ophthalmic Solutions , Piperidines/adverse effectsABSTRACT
The safety and efficacy of two birch pollen extracts, one chemically conjugated to alginate (Anjuvac) the other adsorbed to aluminium hydroxide (Alutard), were investigated in an open multicentre comparative study of 63 birch pollen allergic patients. Both extracts decreased the nasal symptoms during the birch pollen season. The changes in specific IgE and IgG were much the same in both treatment groups. The adverse reactions recorded were mild in both groups, but more frequent in the Anjuvac group, probably because of a more aggressive dose schedule though there were twice as many asthmatics in the Anjuvac group. The two investigated allergen extracts were useful alternatives for immunotherapy.
Subject(s)
Alginates/administration & dosage , Aluminum Hydroxide/administration & dosage , Hypersensitivity/therapy , Immunotherapy/methods , Pollen/immunology , Adolescent , Adult , Alginates/adverse effects , Aluminum Hydroxide/adverse effects , Female , Humans , Immunoglobulin E/analysis , Immunoglobulin G/analysis , Injections, Subcutaneous , Male , Middle Aged , Multicenter Studies as Topic , Plant Extracts/immunology , Random Allocation , Scandinavian and Nordic Countries , Skin Tests/methods , TreesABSTRACT
Secretory leukocyte protease inhibitor (SLPI) and alpha-1-proteinase inhibitor (alpha-1-PI), both inhibitors of granulocyte elastase, were studied in nasal secretions from healthy persons and from patients with allergic rhinitis and common cold. SLPI and granulocyte elastase were found in all samples, while alpha-1-PI was lacking in several. In all three groups SLPI was found in an active form and in excess of granulocyte elastase, which thus was completely inhibited. The results indicate that SLPI is the main inhibitor in nasal secretions and that alpha-1-PI plays a minor role.
Subject(s)
Common Cold/metabolism , Nasal Mucosa/metabolism , Protease Inhibitors/analysis , Rhinitis, Allergic, Seasonal/metabolism , Granulocytes/enzymology , Humans , Pancreatic Elastase/analysisABSTRACT
Variation in nasal patency can be studied by rhinomanometry as well as by nasal expiratory and inspiratory peak flow rate. The accuracy of 12 sets of peak flow meters was tested in a standardized way using a pump. Differences between flow meters were found. Consequently it is recommended for a patient to use the same flow meter throughout a study. Comparison between nasal expiratory and inspiratory peak flow was performed before and after provocation of 12 grass pollen-allergic patients. Inspiratory peak flow showed certain advantages compared with expiratory peak flow measurements. The results can best be expressed as the means rather than the top values of three consecutive registrations. Twelve healthy subjects were also tested with rhinomanometry, nasal expiratory and inspiratory peak flow before and after decongestion with nose spray. Comparisons among the three methods showed significant correlations.
Subject(s)
Nose/physiology , Pulmonary Ventilation , Adult , Airway Resistance , Humans , Manometry , Peak Expiratory Flow RateABSTRACT
Fifty-four adult patients with tree pollen-induced rhinitis (28), asthma (1), or rhinitis and asthma (25) were selected for immunotherapy with standardized and partly purified tree pollen extracts using a double blind protocol. The selection was based on clinical history, results of nasal or bronchial challenge, skin prick tests and RAST. Further, based on crossed radio-immunoelectrophoresis, sex, age and severity of symptoms, the patients were allocated in matched pairs and the treatment alternatives were randomly distributed within the pairs. Twenty-three patients treated with extracts composed of any combination of alder, birch and hazel pollen which matched their IgE response in CRIE (Group 1 (ABC)) and 22 patients receiving birch pollen extracts (Group 2 (B)) completed all 3 years of treatment. The in vivo results comprising symptom and medicine consumption scores are given here. Changes in specific skin and nasal reactivity as well as in immunological parameters are presented separately. No significant differences were demonstrated between the treatment groups in the two parameters. Both extracts were effective and reduced in general the symptom scores to one tenth of the starting level. Expressed another way, at the end of the study, the patients tolerated 30 times more pollen until symptoms of the same severity were elicited, compared to before. In the Nordic countries, spring-time asthma and rhino-conjunctivitis caused by pollen from deciduous trees can be effectively treated with an extract of birch pollen alone.
Subject(s)
Desensitization, Immunologic/methods , Pollen/analysis , Rhinitis, Allergic, Seasonal/therapy , Adolescent , Adult , Aged , Asthma/complications , Asthma/therapy , Clinical Trials as Topic , Conjunctivitis, Allergic/complications , Conjunctivitis, Allergic/therapy , Double-Blind Method , Female , Humans , Male , Middle Aged , Rhinitis, Allergic, Seasonal/complications , TreesABSTRACT
Patients allergic to tree pollen entered a 3-year course of immunotherapy (1980-83) with either birch pollen extracts alone (n = 26) or patient-tailored extracts of birch, alder and hazel pollen (n = 27). The clinical and immunological results of this study are published elsewhere. This paper contains an evaluation of skin prick test and nasal provocation test results. There were no significant differences between the two treatment groups concerning these two parameters. In both groups the allergen-specific sensitivity in the skin showed seasonal variations but a significant decrease. During the years of treatment there was also a significant decrease in the specific sensitivity of the nasal mucosa. With the present demands for purification and standardization of allergen extracts it is of practical and economic interest to know that tree pollen-allergic patients showing positive reactions to birch, alder and hazel extracts can be effectively treated using birch pollen extract alone.
Subject(s)
Desensitization, Immunologic/methods , Pollen/analysis , Rhinitis, Allergic, Seasonal/therapy , Asthma/complications , Asthma/therapy , Clinical Trials as Topic , Conjunctivitis, Allergic/complications , Conjunctivitis, Allergic/therapy , Double-Blind Method , Humans , Nasal Provocation Tests , Rhinitis, Allergic, Seasonal/complications , Skin Tests , TreesABSTRACT
Patients allergic to pollen from alder, birch and hazel were hyposensitized during a 3-year period with either birch pollen extract alone (n = 24) or a mixture of one or more of alder, birch and hazel pollen extracts (n = 27). The effect of the treatment was evaluated by RAST and tandem crossed-radioimmunoelectrophoresis (tandem-CRIE). The patient' specific IgE response to the major allergens of alder (Aln g I), birch (Bet v I) and hazel (Cor a I and Cor a II), as measured by tandem-CRIE, and the total specific IgE response, measured by RAST, decreased significantly (Pc less than 0.05) during immunotherapy, irrespective of the extract used during the treatment. There was no significant difference (Pc less than 0.05) between the two treatment groups. The results obtained indicate either that birch pollen extract alone is adequate in the treatment of the studied patient group or the patients had been sensitized towards birch pollen alone.